(57 days)
Not Found
Not Found
No
The summary describes a standard immunoassay for measuring thyroxine levels and does not mention any AI or ML components.
No.
This device is an in vitro diagnostic assay used to measure total T in human serum and plasma, which aids in the assessment of thyroid status. It does not directly provide therapy or treatment to a patient.
Yes
The device is described as an aid in the assessment of thyroid status, which indicates it provides information to diagnose a condition.
No
The device description clearly states it is a Chemiluminescent Microparticle Immunoassay (CMIA), which is a laboratory-based assay involving chemical reactions and physical components (microparticles), not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "quantitative determination of thyroxine (total T.) in human serum and plasma." This involves testing biological samples in vitro (outside the body).
- Device Description: The description confirms it's a "Chemiluminescent Microparticle Immunoassay (CMIA)" for analyzing human serum or plasma. This is a common method used in IVD testing.
- Aid in Assessment: The intended use also states it's to be used as an "aid in the assessment of thyroid status." This indicates the results are used to help diagnose or monitor a medical condition, which is a key characteristic of an IVD.
The information provided clearly aligns with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The ARCHITECT™ Total T (TT ) assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of thyroxine (total T.) in human serum and plasma. The ARCHITECT Total T assay is to be used as an aid in the assessment of thyroid status.
Product codes (comma separated list FDA assigned to the subject device)
KLI, JIT, JJX
Device Description
ARCHITECT Total T, is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of total T , in human serum or plasma (lithium heparin, sodium heparin. or potassium EDTA). ARCHITECT Total T, is calibrated with ARCHITECT Total T, Calibrators. ARCHITECT Total T, Controls are assayed for the verification of the accuracy and precision of the Abbott ARCHITECT i System.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Substantial equivalence has been demonstrated between the ARCHITECT Total T. assay and the AxSYM® Total T. assay. The intended use of both assays is for the quantitative determination of total T. in human serum and plasma. Least squares linear regression analysis of an ARCHITECT Total T. vs. AxSYM Total T. comparison, using 1155 specimens, gave the following parameter estimates: correlation coefficient = 0.928. slope = 1.01 and y-axis intercept = - 0.11 ug/dL. Passing-Bablok linear regression analysis of an ARCHITECT Total T, vs. AxSYM Total T, comparison, using 1155 specimens, gave the following parameter estimates: correlation coefficient = 0.928, slope = 0.99 and yaxis intercept = - 0.13 ug/dL.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
correlation coefficient = 0.928, slope = 1.01 and y-axis intercept = - 0.11 ug/dL (Least Squares)
correlation coefficient = 0.928, slope = 0.99 and y-axis intercept = - 0.13 ug/dL (Passing-Bablok)
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1700 Total thyroxine test system.
(a)
Identification. A total thyroxine test system is a device intended to measure total (free and protein bound) thyroxine (thyroid hormone) in serum and plasma. Measurements obtained by this device are used in the diagnosis and treatment of thyroid diseases.(b)
Classification. Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
KC983440
510(k) Summary Abbott ARCHITECT™ Total Ta
Summary of Safety and Effectiveness Information Supporting a Substantially Equivalent Determination
The following information as presented in the Premarket Notification [510(k)] for Abbott ARCHITECT™ Total T, constitutes data supporting a substantially equivalent determination.
ARCHITECT Total T, is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of total T , in human serum or plasma (lithium heparin, sodium heparin. or potassium EDTA). ARCHITECT Total T, is calibrated with ARCHITECT Total T, Calibrators. ARCHITECT Total T, Controls are assayed for the verification of the accuracy and precision of the Abbott ARCHITECT i System.
Substantial equivalence has been demonstrated between the ARCHITECT Total T. assay and the AxSYM® Total T. assay. The intended use of both assays is for the quantitative determination of total T. in human serum and plasma. Least squares linear regression analysis of an ARCHITECT Total T. vs. AxSYM Total T. comparison, using 1155 specimens, gave the following parameter estimates: correlation coefficient = 0.928. slope = 1.01 and y-axis intercept = - 0.11 ug/dL. Passing-Bablok linear regression analysis of an ARCHITECT Total T, vs. AxSYM Total T, comparison, using 1155 specimens, gave the following parameter estimates: correlation coefficient = 0.928, slope = 0.99 and yaxis intercept = - 0.13 ug/dL.
In conclusion, these data demonstrate that the ARCHITECT Total T2 assay is as safe and effective as, and is substantially equivalent to, the AxSYM Total Ta assay.
Prepared and Submitted September 28, 1998 by: April Veoukas, J.D. Senior Regulatory Specialist ADD Regulatory Affairs (847) 937-8197 Abbott Laboratories 200 Abbott Park Road Abbott Park, IL 60064-3537
ARCHITECT™ Total T2 510(k) September 1998
1
Public Health Service
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/1/Picture/2 description: The image shows a partial view of a document with a seal and some text. The seal on the left includes the words "DEPARTMENT OF HEALTH & HUMA". To the right of the seal, the text "NOV 25" is visible, suggesting a date or reference number. The document appears to be official, possibly from a government or health-related organization.
NOV 2 5 1998
Ms. April Veoukas, J.D. Senior Regulatory Specialist ADD Requaltory Affairs Abbott Laboratories 200 Abbott Park Road Abbott Park, Illinois 60064-3537
Re: K983440 Trade Name: Abbott ARCHITECT™ Total T. Regulatory Class: II Product Code: KLI JIT II JJX I Dated: September 28, 1998 September 29, 1998 Received:
Dear Ms. Veoukas:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General requlation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
2
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbrandinq by reference to premarket notification"(21 CFR 807.97). Other qeneral information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
510(k) Number (if known): $98340
Abbott ARCHITECT™ Total T4 Device Name: _________________________________________________________________________________________________________________________________________________________________
Indications For Use:
The ARCHITECT™ Total T (TT ) assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of thyroxine (total T.) in human serum and plasma. The ARCHITECT Total T assay is to be used as an aid in the assessment of thyroid status.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Image /page/3/Figure/5 description: The image shows the concurrence of CDRH, Office of Device Evaluation (ODE). There are two options: Prescription Use (Per 21 CFR 801.109) or Over-The-Counter Use (Optional Format 1-2-96). An arrow points to the Prescription Use option.
sion Sign-Off)
ical Laboratory Devices
510(k) Manager K983446